Skip to main content
Premium Trial:

Request an Annual Quote

Natera Joins UnitedHealthcare's Preferred Lab Network

NEW YORK – Natera said on Thursday that it has been selected to participate in UnitedHealthcare’s Preferred Laboratory Network (PLN), effective July 1.

The company joins 11 other laboratories participating in the PLN program in 2022 — Aegis Sciences, AmeriPath, BioReference Laboratories, Clinical Pathology Laboratories, Invitae, Laboratory Corporation of America, Mayo Clinic Laboratories, Millennium Health, Myriad Genetics, Neogenomics, and Quest Diagnostics.

UHC launched the PLN in 2019, with participating labs meeting its highest levels of quality, service, and cost criteria. While patients can still receive covered lab services from any of UHC's roughly 300 member labs, the insurer incentivizes patients to use PLN labs by reducing out-of-pocket costs at those labs.

All labs in the UHC network are eligible to apply for inclusion in the PLN, and labs that are not selected can reapply on an annual basis. Since the program launched, it has expanded from six to 12 participating labs.

"Natera is pleased to be part of UnitedHealthcare's PLN and we look forward to continuing to provide UHC plan members with an outstanding experience," Matthew Mega, VP of market access at Natera, said in a statement. "We remain committed to making personalized genetic testing and diagnostics part of the standard of care."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.